{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:19:23Z","timestamp":1776125963685,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2020\/ABM\/04\/00002-00"],"award-info":[{"award-number":["2020\/ABM\/04\/00002-00"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2019\/35\/B\/NZ3\/03577"],"award-info":[{"award-number":["UMO-2019\/35\/B\/NZ3\/03577"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/0-154-01\/503-01-001-19-00"],"award-info":[{"award-number":["503\/0-154-01\/503-01-001-19-00"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bbrc.2023.149133","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T03:40:05Z","timestamp":1697600405000},"page":"149133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Immunohistochemical detection of EGFRvIII in glioblastoma \u2013 Anti-EGFRvIII antibody validation for diagnostic and CAR-T purposes"],"prefix":"10.1016","volume":"685","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-6052","authenticated-orcid":false,"given":"Adrianna","family":"Rutkowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1397-7166","authenticated-orcid":false,"given":"Tadeusz","family":"Str\u00f3zik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9262-4010","authenticated-orcid":false,"given":"Krystyna","family":"J\u0119drychowska-Da\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Zamerska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Jesionek-Kupnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Och","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u0142a\u017cej","family":"Sz\u00f3stak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-3155","authenticated-orcid":false,"given":"Cezary","family":"Tr\u0119da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"W\u0142odarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Kierasi\u0144ska-Ka\u0142ka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-9534","authenticated-orcid":false,"given":"Tomasz","family":"Wasiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-539X","authenticated-orcid":false,"given":"Damian","family":"Ciunowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rieske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewelina","family":"Stoczy\u0144ska-Fidelus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2023.149133_bib1","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2023.149133_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jha2.356","article-title":"CAR T cell therapy in solid tumors: a review of current clinical trials","volume":"3","author":"Patel","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.bbrc.2023.149133_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2023.149133_bib4","article-title":"Twenty years after glioblastoma multiforme diagnosis: a case of long-term survival","volume":"13","author":"Rabab\u2019h","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.bbrc.2023.149133_bib5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","article-title":"Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014","volume":"4","author":"Ostrom","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbrc.2023.149133_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trsl.2017.07.003","article-title":"Chimeric antigen receptor T-cell therapy for glioblastoma","volume":"187","author":"Rodriguez","year":"2017","journal-title":"Transl. Res."},{"key":"10.1016\/j.bbrc.2023.149133_bib7","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","article-title":"Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors","volume":"23","author":"Felsberg","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149133_bib8","article-title":"ErbB2\/HER2-Specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2023.149133_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7150\/jca.16108","article-title":"Low incidence along with low mRNA levels of EGFRvIII in prostate and colorectal cancers compared to glioblastoma","volume":"8","author":"Peciak","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbrc.2023.149133_bib10","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/00006123-199912000-00034","article-title":"Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens","volume":"45","author":"Feldkamp","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1016\/j.bbrc.2023.149133_bib11","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/onc.2012.280","article-title":"EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms","volume":"32","author":"Del Vecchio","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.149133_bib12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbrc.2023.149133_bib13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ebiom.2015.08.026","article-title":"The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes","volume":"2","author":"Xie","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbrc.2023.149133_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155230","article-title":"EGFR activation leads to cell death independent of PI3K\/AKT\/mTOR in an AD293 cell line","volume":"11","author":"Treda","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2023.149133_bib15","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8201","article-title":"Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes","volume":"7","author":"Stec","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2023.149133_bib16","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2023.149133_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/30.9.e36","article-title":"Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR","volume":"30","author":"Pfaffl","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2023.149133_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065444","article-title":"Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients","volume":"8","author":"Bie\u0144kowski","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2023.149133_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11060-010-0352-0","article-title":"Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies","volume":"102","author":"Witusik-Perkowska","year":"2011","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.bbrc.2023.149133_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087136","article-title":"The failure in the stabilization of glioblastoma-derived cell lines: spontaneous in vitro senescence as the main culprit","volume":"9","author":"Stoczynska-Fidelus","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2023.149133_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-021-04306-1","article-title":"Web-based LinRegPCR: application for the visualization and analysis of (RT)-qPCR amplification and melting data","volume":"22","author":"Untergasser","year":"2021","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.bbrc.2023.149133_bib22","article-title":"Sensitivity of neoplastic cells to senescence unveiled under standard cell culture conditions","volume":"35","author":"Zieba","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2023.149133_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6130-2","article-title":"A way to understand idiopathic senescence and apoptosis in primary glioblastoma cells - possible approaches to circumvent these phenomena","volume":"19","author":"Janik","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2023.149133_bib24","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.bbrc.2023.149133_bib25","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-06-0913","article-title":"Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting","volume":"12","author":"Sok","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149133_bib26","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1158\/1078-0432.CCR-10-3338","article-title":"Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment","volume":"17","author":"Tinhofer","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149133_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1349-7006.2003.tb01351.x","article-title":"Expression of constitutively activated EGFRvIII in non-small cell lung cancer","volume":"94","author":"Okamoto","year":"2003","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbrc.2023.149133_bib28","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/hum.2012.041","article-title":"Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma","volume":"23","author":"Morgan","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbrc.2023.149133_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1092587","article-title":"EGFRvIII: an oncogene with ambiguous role","volume":"2019","author":"Rutkowska","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.bbrc.2023.149133_bib30","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1101\/gad.303453.117","article-title":"The power of the few","volume":"31","author":"Chen","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrc.2023.149133_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012129","article-title":"Phenotypical flexibility of the EGFRvIII-positive glioblastoma cell line and the multidirectional influence of TGF\u03b2 and EGF on these cells\u2014EGFRvIII appears as a weak oncogene","volume":"23","author":"W\u0142odarczyk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2023.149133_bib32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/neuonc\/nov013","article-title":"Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas","volume":"17","author":"Van Den Bent","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbrc.2023.149133_bib33","doi-asserted-by":"crossref","first-page":"8560","DOI":"10.18632\/oncotarget.24058","article-title":"Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation","volume":"9","author":"Stec","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2023.149133_bib34","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.149133_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054350","article-title":"Increased EGFRvIII epitope accessibility after tyrosine kinase inhibitor treatment of glioblastoma cells creates more opportunities for immunotherapy","volume":"24","author":"Tr\u0119da","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2023.149133_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23012275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23012275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:34:13Z","timestamp":1757766853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23012275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":36,"alternative-id":["S0006291X23012275"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.149133","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical detection of EGFRvIII in glioblastoma \u2013 Anti-EGFRvIII antibody validation for diagnostic and CAR-T purposes","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.149133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"149133"}}